Summary Fluid transport parameters in intracranial tumours influence the delivery of therapeutic agents and the resolution of peritumoral oedema. The tumour and cortex interstitial fluid pressure (IFP) and the cerebrospinal fluid pressure (CSFP) were measured during the growth of brain and pial surface tumours [R3230AC mammary adenocarcinoma (R3230AC) and F98 glioma (F98)] in rats. Intratumoral and intracranial pressures were also measured in rodents and patients treated with dexamethasone, mannitol and furosemide (DMF), and hypocapnia. The results show that (1) for the R3230AC on the pial surface, IFP increased with tumour volume and CSFP increased exponentially for tumours occupying a brain volume of 5% or greater; (2) in F98 with volumes of approximately 10 mm3, IFP decreased from the tumour to the cortex, whereas for tumour volumes > 16 mm3 IFP equilibrates between F98 and the cortex; (3) DMF treatment reduced the IFP of intraparenchymal tumours significantly and induced a pressure gradient from the tumour to the cortex; and (4) in 11 patients with intracranial tumours, the mean IFP was 2.0 ± 2.5 mmHg. In conclusion, the IFP gradient between intraparenchymal tumours and the cortex decreases with tumour growth, and treatment with DMF can increase the pressure difference between the tumour and surrounding brain. The results also suggest that antioedema therapy in patients with brain tumours is responsible in part for the low tumour IFP.
Studies from our group and other investigators have shown that the interstitial fluid pressure (IFP) of human tumours in situ is significantly elevated compared with normal tissues Roh et al, 1991; Gutmann et al, 1992; Less et al, 1992; Curti et al, 1993; Arbit et al, 1994; Nathanson and Nelson, 1994) . In most normal tissues the IFP is around 0 mmHg while for the different carcinoma types measured to date the mean IFPs vary between 14 and 30 mmHg. In general, in human and experimental tumours the IFP increases with tumour size (Jain, 1987a; Boucher et al, 1990 Boucher et al, , 1991 Boucher et al, , 1995 Gutmann et al, 1992; Lee et al, 1992; Nathanson and Nelson, 1994) . However, in other studies, the IFP was found to be independent of the tumour volume (Less et al, 1992; Curti et al, 1993; Boucher et al, 1995; Tufto and Rofstad, 1995; Znati et al, 1996) . Measurements in experimental tumours have demonstrated that (1) the IFP is uniform throughout the centre of tumours and drops steeply in the tumour periphery or in the normal tissue surrounding the tumour (Boucher et al, 1990; Boucher and Jain, 1992; DiResta et al, 1993) and (2) that the hydrostatic and oncotic pressures in the vascular and interstitial space are at or close to equilibrium Jain, 1989, Boucher and Stohrer et al, 1995) . The similarity in hydrostatic pressures between the microvascular and interstitial space is thought to be a major mechanism limiting the convective delivery of large therapeutic agents to solid tumours (Jain and Baxter, 1988) .
In a recent study, Arbit et al (1994) measured, at craniotomy, the IFP in brain tumours and in the cortex and found that the mean IFPs were 7.0 and 0.8 mmHg respectively. In untreated patients with brain tumours, mean CSFP was found to vary between 24 and 33 mmHg (Kullberg and West, 1965; Miller and Leech, 1975; Alberti et al, 1978) . The lower pressures in the cortex and tumour are probably not due to pressure differences between the ventricles and the parenchyma as, under normal conditions, CSFP and intraparenchymal IFP are similar (Poll et al, 1972; Wiig and Reed, 1983) and, in the case of brain lesions, intraparenchymal IFP is similar or higher than CSFP (Reulen and Kreysch, 1973; Reulen et al, 1977 : Sundbarg et al, 1987 . The low IFP in intracranial tumours at craniotomy is probably due to the management of patients with agents and procedures (e.g. dexamethasone, mannitol, furosemide (DFM), hypocapnia and opening of the intracranial cavity) that can lower the tumour IFP as well as the intracranial pressure.
The goals of the present study were: (1) to measure at craniotomy the tumour and the surrounding brain IFP in patients treated with DMF and hypocapnia (2) to characterize the parameters that determine IFPs in tumours growing in the intracranial cavity; (3) to measure the pressure gradients between the tumour and the surrounding brain as a function of tumour size; and (4) to determine the modifications in CSFP and intracranial tumour IFP induced by DMF treatment and hypocapnia. To accomplish goals 2,3 and 4, the IFP was measured in two rat tumours [R3230AC mammary adenocarcinoma (R3230AC) and F98 glioma (F98)] implanted on the pial surface and in the brain parenchyma. In the R3230AC implanted on the pial surface, the IFP was measured as a function of tumour size, and the relationship between the microvascular pressure (MVP) and IFP was determined. In F98 tumours in the brain parenchyma, the IFP gradients from the tumour to the cortex were measured as a function of tumour size and DMF treatment.
MATERIAL AND METHODS Animal protocol

Surgery and tumour implantation
Fisher rats (150-180 g) The animals were anaesthetized with a mixture of ketamine and xylazine (100 mg and 10 mg kg-'). With a dentist's drill, two 3-mm holes were made through the bone on each side of the sagittal suture. The centre of the two holes was located 2 mm from the sagittal suture and 2 mm caudate to the coronal suture. In both openings the dura was removed. For pial surface tumours a piece of R3230AC or F98 tumour (1 x 1 x 1 mm) from a donor animal was introduced on the left side and a plastic cover slip was secured to the bone with cyanocrylate glue to close the opening. The other opening was also closed with a cover slip after introducing artificial CSF. Intraparenchymal tumours were also implanted following the preparation of a 3-mm opening in the bone at the same location as for pial surface tumours. Tumour slurry was prepared from pieces of R3230AC or F98 tumours and introduced into a Hamilton syringe linked to a 23-gauge needle. With a stereotaxic device the tip of the 23-gauge needle was placed 2 mm below the pial surface, and 20 gl of tumour slurry was injected. The opening was closed as previously described. To measure CSFP, 1-mm depressions occupying three-quarters of the bone thickness were drilled 1.5 mm from the sagittal suture and 0.5 mm caudate to the coronal suture.
As it was not possible to measure the microvascular pressure of the superficial microvessels of pial tumours through the 3-mm openings, an 8-mm opening was prepared over the two hemispheres with a dentist's drill. The dura was removed, and after introducing a piece of R3230AC the opening was closed with a plastic cover slip. The cover slip was perforated with four holes (diameter approximately 2 mm) and covered on one side with a thin transparent plastic wrap. Another cover slip was glued over the perforated cover slip.
Preparation of animals for IFP measurements
The animals were anaesthetized with chloral hydrate (300 mg kg-') and placed on a heating pad to maintain the body temperature between 36°C and 37°C. The left femoral artery was cannulated for measurement of arterial pressure and blood gases. The left femoral vein was cannulated for injection of saline, Evans blue or lissamine green. The animals were connected to an artificial ventilator following tracheotomy, and Pavalon (0.2 mg kg-') was given. All the IFP and MVP measurements were accepted as valid when the mean arterial pressure was greater than 70 mmHg and the Paco2 was between 30 and 45 mmHg.
IFP and MVP measurements IFP was measured with the micropipette technology described previously (Boucher et al, 1990; Boucher and Jain, 1992) . In the R3230AC on the pial surface, IFP was measured in four different groups on day 6, 10, 14-15 and 17-20 after tumour implantation. The cover slip was removed, and artificial CSF (35-37°C) was superfused continuously on the tumour surface. In the smaller tumours on days 6 and 10, IFP was measured in the centre of the tumour at a distance of approximately 0.5-1.0 mm from the tumour surface. In the day 14-15 and 17-20 groups with the tumour thickness varying between 3.5 and 6.0 mm, only the IFP measurements obtained at a distance 2 0.5 mm from the tumour surface were used for data analysis. Following completion of the IFP measurements in the tumour, CSFP was measured through the 1-mm opening over the ventricle with a blunt 26-gauge needle connected to a pressure transducer. The thin layer of bone that remained in the 1-mm hole was easily perforated by carefully pushing the 26-gauge needle through the bone.
For measurement of MVP and IFP in the large windows, the first cover slip was removed and small holes were punctured through the transparent plastic wrap with a 30-gauge needle to have access to the tumour with micropipettes. Larger holes resulted in bulging of the tumour through the opening. MVP was measured in vessels with diameters between 40 and 100 gm.
To verify that the tip of the micropipette was in the lumen of the tumour vessels, fast green (0.5%) was infused via the micropipette. MVP measurements were considered valid when the fast green disappeared rapidly with blood flow following the infusion. MVP was compared with the IFP measured at a distance . 0.5 mm from the tumour surface.
Measurement in intraparenchymal tumours was done in R3230AC with tumour volumes between 50 and 175 mm3 and in F98 gliomas with volumes between 10 and 70 mm3. In both tumour types, the IFP was measured with micropipettes in the tumour and the surrounding brain. Manipulation of tumour and cortex IFP, and CSFP Animals with F98 and R3230AC tumours implanted on the pial surface or in the parenchyma were treated with DMF. The animals were treated once daily with dexamethasone (3 mg kg-', i.p.), and for 3-4 days before the measurements. The last injection of dexamethasone was given 3-4 h before the IFP was measured.
Mannitol (2.5 g kg-', at a rate of 0.25 ml min-' over a period of 10 min) was given first followed by furosemide (2 mg kg-') 15 min . The IFP in the tumours was measured following the opening of the intracranial cavity and removal of the dura. In five cases, IFP was also measured in the brain surrounding the tumour.
RESULTS
Measurements in rodents
To test if the opening of the intracranial cavity to the atmosphere would induce changes in intratumoral pressure and CSFP, both pressures were monitored following removal of the cover slip. The pressures remained stable after removal of the cover slip. Figure To assess the influence of Paco2 on the tumour (R3230AC) IFP, the IFP was measured before and after modification of the rate and volume of ventilation in ten animals. In all the animals, there was a decrease in tumour IFP which varied between 17% and 50% at mean values of Paco2, which decreased from 36 ± 2.5 to 24.5 ± 2. In pial surface tumours in large windows, the MVP of superficial vessels was compared with the IFP in the central regions of the tumours. The IFP was high and uniform in the tumour centre and generally dropped to lower values at 0.5 mm or less from the tumour surface. The IFP at 2 0.5 mm from the surface and the MVP were closely related ( Figure 1B) . The comparison between the MVP in superficial vessels and the central IFP assumes that the MVP of superficial and central vessels are similar .
Treatment with DMF and hypocapnia induced a significant decrease in the IFP of R3230AC implanted on the pial surface. IFP was 19.5 ± 7.0 mmHg in the control group and 8.0 ± 3.0 mmHg in the treated group (Table 1) . In F98 tumours on the pial surface, IFP was similar in the control and treated groups. In animals with F98 and R3230AC tumours, the CSFP was significantly decreased by DMF treatment and hypocapnia (Table 1) .
The tumours implanted in the brain parenchyma were identified by the blue coloration resulting from the intravenous injection of lissamine green. In the F98 and R3230AC tumours implanted in the parenchyma, the tumour-cortex interface was located at 1.5-2.0 mm from the pial surface. For the pressure measurements, the micropipettes were introduced at depths of 3.5-4.0 mm from the pial surface; the IFP was measured for 20-30 s at intervals of 200-400 ,um as the micropipette was retrieved to the pial surface. Depending on the fluid communication between the tumour and the micropipette, 3-8 IFP measurements were obtained thus permitting the characterization of IFP profiles from the tumour to the surrounding cortex. In animals with small F98 tumours (approximately 10 mm3), the IFP (five out of seven pressure profiles) generally increased within a distance of 2.0-2.5 mm from the pial surface, which corresponds to the tumour-cortex interface or the peripheral regions of the tumours (Figure 2) . In two pressure profiles, the IFP did not increase from the cortex to the tumour; the IFP in the tumour and in the cortex were similar. This type of IFP profile could be because of the location of the micropipette in the tumour periphery or in the surrounding cortex. In larger F98 tumours with volumes between 16 and 36 mm3, all the IFP profiles were uniform except for the pressure increase at a distance of 1.0 mm or less from the pial surface (Figure 2 ). In contrast, in animals treated with DMF and with tumour volumes between 13 and 70 mm3, IFP (eight out of nine pressure profiles) increased at 2.0-2.5 mm from the pial surface (Figure 2 ). The IFP in the tumour and cortex as well as the CSFP were significantly decreased by DMF treatment and hypocapnia (Table 1) .
In R3230AC implanted in the parenchyma, the tumour volumes were larger than the F98 gliomas in both the control (52-150 mm3) and treated (61-174 mm3) groups. Similar to the larger F98 tumours, in animals with R3230AC, the IFP in the tumour and the cortex were similar (Table 1 ). The IFP increased at less than 0.5 mm from the pial surface. In animals treated with DMF and hypocapnia, the IFP (six out of eight pressure profiles) increased at 2.0-2.5 mm from the pial surface. Compared with the control group, DMF treatment and hypocapnia significantly reduced the IFP in the tumour and in the surrounding brain and induced a nonsignificantly decrease in CSFP (Table 1) .
For all the intraparenchymal tumours, in order to calculate mean values of IFP, IFPs at > 2.0 mm from the pial surface were used to calculate the mean tumour IFP, whereas the mean IFPs in the cortex were determined from IFP measurements at less than 2.0 mm from the pial surface. This definition of the border between the tumour and the cortex was based on the location of the tumour-cortex interface at 1.5-2.0 mm from the pial surface and on the fact that, in animals with small F98 tumours or in animals treated with DMF, the IFP increased at 2.0-2.5 mm from the pial surface. The data were characterized by two types of analyses. In the type 1 analysis, all the IFP measurements in the tumour and in the cortex were included. The type II analysis included all the IFP profiles in the experimental groups with large F98 and R3230AC tumours as well as the IFP profiles that had an increasing IFP from the cortex to the tumour in animals treated with DMF and hypocapnia and animals with small F98 tumours. The exclusion of the IFP profiles that did not show a pressure increase from the cortex to the tumour was based on the possibility that the micropipettes could have been located in the periphery of the tumour or in the cortex surrounding the tumour. The type I and II analyses are given, respectively, in Table 1 and 2. In general, there was a good agreement between the results of the type I and II analyses. The main difference was found in R3230AC tumours treated with DMF. The type II analysis revealed that the IFP was significantly higher in the tumour than in the cortex (Table 2) . With both types of analyses, there was a significant pressure difference between the tumour and the ventricle in animals with F98 tumours treated with DMF and hypocapnia, whereas, in animals with R3230AC tumours that were treated with DMF and hypocapnia, the CSFP and tumour IFP were similar (Table 1 and 2). There was no significant difference between the cortex IFP and the CSFP in treated and non-treated animals with F98 and R3230AC tumours. In general the cortex IFP was similar or higher than the CSFP, except in treated animals with large R3230AC tumours for which the CSFP was higher than the cortex IFP. Following the intravenous injection of lissamine green both F98 and R3230AC became blue, thus demonstrating the absence of a blood-tumour barrier in these two tumour types. The treated and non-treated R3230AC and F98 tumours were also permeable to albumin as indicated by Evans blue.
Measurements in patients
The IFP was measured in 11 patients with an astrocytoma, glioblastoma, meningioma or ganglioglioma (Table 3 ). The IFP in 10 of 11 tumours varied between 0.0 and 3.0 mmHg. In one astrocytoma the IFP was 9.5 mmHg. The mean IFP was 2.0 ± 2.5 mmHg. In five cases, the IFP measured in the brain surrounding the tumour varied between 0.5 and 3.5 mmHg. with a mean of 2.0 ± 1.0 mmHg (Table 3 ).
DISCUSSION
One of the goals of the present study was to characterize the parameters that influence the IFP in intracranial tumours. Similar to peripheral tumours, the IFP in R3230AC on the pial surface increased with tumour size (Jain, 1987a; Boucher et al, 1990 Boucher et al, , 1991 Boucher et al, , 1995 Gutmann et al, 1992; Lee et al, 1992; Nathanson and Nelson, 1994) . In R3230AC implanted on the pial surface, the MVP and IFP were similar (Figure iB) , thus suggesting that the increase in IFP with tumour size was due to the increasing MVP. In peripheral tumours as well as in tumours implanted on the pial surface, the high vascular permeability (Jain, 1987b; Yuan et al, 1994 Yuan et al, , 1995 and the absence of a functional lymphatic circulation (Taginawa et al, 1981) are probably responsible for the equilibration in oncotic and hydrostatic pressures between the microvascular and interstitial space (Jain, 1987b; Boucher and Jain, 1992 (Wiig and Gadeholt, 1985; Zlotecki et al, 1993 Zlotecki et al, , 1995 . Arteriovenous pressure modifications in the cerebral microcirculation could also contribute to the increase in tumour MVP and IFP, especially when the mass effect produced by the tumour induces a steep increase in CSFP ( Figure IA) . It has been demonstrated that the cerebral venous pressure (CVP) increases in parallel with the CSFP and it is always kept slightly higher than the CSFP. Parallel modifications in CSFP and CVP can be induced by the inflation of intracranial balloons or by the modification of the PaCO2 (Yada et al, 1973; Luce et al, 1982; Wiig and Reed, 1983) . Thus, the increase in the CVP of the vessels draining the tumour could lead to a further increase in the tumour MVP and IFP.
Pressure gradients have been evaluated in the normal brain and after inducing lesions in the cortex. In two studies in normal brain, no pressure gradients were found between CSF and the grey or white matter (Poll et al, 1972; Wiig and Reed, 1983) . Reulen and collaborators (Reulen and Kreysch, 1973; Reulen et al, 1977) measured pressures in the normal brain and in a cold lesion model of the cortex. Under normal conditions, they measured higher pressures in the CSF than in the white matter, and the lesion in the cortex induced higher pressures close to the lesion compared with the ventricles and distant sites in the white matter. Our results show that, in F98 gliomas with volumes of approximately 10 mm3, there is a pressure gradient from the tumour to the cortex. At tumour volumes > 16 mm3, which is approximately 1% of the brain volume of a rat, the IFP equilibrates between the tumour and the surrounding cortex (Figure 2 and Table 1 ). The decrease in pressure gradient from the tumour to the cortex is probably due to fluid filtration from tumour vessels. With increasing tumour size, the number of tumour vessels with high filtration rates increases thus surpassing the drainage capacity of the surrounding brain and thus inducing the pressure build-up. The pressure equilibration between the tumour and the surrounding tissue decreases the filtration of fluid towards an equilibrium that determines the extent of peritumoral oedema (Reulen et al, 1990) . Pressure equilibration could be favoured by the absence of lymphatics in the cortex and the high resistance to bulk flow offered by the tortuous organization of the interstitial space of the grey matter (Fenstermacher, 1984) . In contrast, we have shown that the IFP was uniform throughout subcutaneous tumours and dropped steeply at the tumour-skin interface (Boucher et al, 1990 (Leenders et al, 1985; Reichman et al, 1986; Nakagawa et al, 1988; Neuwelt et al, 1993) . Systemic infusions of mannitol can induce significant decreases in CSFP as well as in the water content of the normal brain and brain tumours (Bell et al, 1987; Ravussin et al, 1988; Hartwell and Sutton, 1993) . The decrease in intracranial pressure induced by mannitol has been associated with osmotic shifts of water from the interstitial space to blood. Muizelaar et al (1983) (Weiss and Nulsen, 1970; Donato et al., 1994 The reduction in the IFP of intraparenchymal tumours and R3230AC on the pial surface could also result from a decrease in water content induced by oncotic and osmotic gradients across tumour vessels. Hyperosmolar solutions have been shown to reduce the water content of brain tumours in patients and in a rodent model (Bell et al, 1987; Hansen et al, 1994) . Hansen et al (1994) found with hypertonic sodium chloride a significant reduction in the water content of a brain glioma in the rat, which was impermeable to Evans blue, however hypertonic sodium chloride was not able to reduce the water content of a cold induced brain lesion permeable to Evans blue. The accumulation of Evans blue in treated and non-treated R3230AC and F98 tumours suggests that mannitol could equilibrate fairly rapidly across the microvascular wall, thus preventing the establishment of an effective osmotic gradient in those tumours. However, from the qualitative evaluation of the extravasation of Evans blue, it is impossible to determine if the oncotic gradient was increased by DMF treatment. As dexamethasone can reduce the accumulation of macromolecules in brain tumours (Reichman et al, 1986; Neuwelt et al, 1993) , the oncotic gradient could be modified by DMF treatment.
IFP in intracranial tumours in patients
In the present study, the mean IFP in brain tumours in patients was 2.0 mmHg, and Arbit et al (1994) recently reported a mean IFP of 7.2 mmHg by averaging the IFPs for meningiomas, glioblastomas and brain metastases. We speculated that the low IFP in brain tumours in patients was because of DMF treatment, hypocapnia and opening of the intracranial cavity as in normal human subjects CSFP can vary between 6 and 17.5 mmHg, with a mean around untreated patients with brain tumours can have mean CSFPs varying between 24 and 33 mmHg depending on the studies (Kullberg and West, 1965; Miller and Leech, 1975; Alberti et al, 1978) . Our experimental results confirm that the IFP in tumours on the pial surface and in the parenchyma is elevated, and that DMF treatment and hypocapnia can reduce significantly the IFP in intracranial tumours (Table 1) . As it was impossible to measure the intratumoral pressure in a control group or before the opening of the intracranial cavity, it is not possible to conclude, in patients, that the low intratumoral IFP resulted exclusively from DMF treatment and hypocapnia. Fluid loss from the intracranial cavity can significantly reduce the CSFP (Lundberg and West, 1965; Gilland et al, 1974) . It is also possible that, because of the lower vascular permeability of some brain tumours (Yuan et al, 1994) , the IFP could be low or similar to the CSFP, especially in turnours not influenced by growth in a confined space. However, even in a tumour with a low vascular permeability, the pressure could be elevated as a result of equilibration with the intracranial pressure.
In summary, the results demonstrate that, similar to some peripheral tumours, the IFP of R3230AC on the pial surface increased with tumour size and the tumour MVP was similar to the IFP. In contrast to subcutaneous tumours, the IFP did not decrease in the periphery of the larger tumours in the cortex; the pressure in the surrounding cortex and in the tumour were equal. Treatment with DMF significantly decreased the IFP of brain tumours and the intracranial pressure, and induced pressure gradients between the tumours and the cortex. The low IFP values in intracranial tumours in patients are due in part to DMF treatment and hypocapnia.
